keyword
MENU ▼
Read by QxMD icon Read
search

Long acting antipsychotics

keyword
https://www.readbyqxmd.com/read/29898284/a-within-subject-consideration-of-the-psychotic-spectrum-disorder-concept-in-a-patient-in-remission-associated-with-cortical-gray-matter-recovery
#1
Herbert Y Meltzer, Min Young Sim, Adam Anderson, Christopher Cannistraci, Karu Jayathilake, Daniel Barrett Share, Myung Lee
INTRODUCTION: Psychotic spectrum disorder (PSD) links the syndromes of bipolar disorder, psychotic depression, and schizophrenia, often viewed as unique disorders. AIMS: Application of the PSD concept to a single patient rather than across groups of patients and demonstration of a remarkable remission of schizophrenia phenotype with recovery of gray matter in specific brain regions. RESULTS: We report a woman who experienced discrete, nonoverlapping periods of each of the above syndromes, in the order noted, over a 30-year period, followed by abrupt ending of psychosis and full remission lasting at least 7 years...
July 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29886522/aripiprazole-once-monthly-as-maintenance-treatment-for-bipolar-i-disorder-a-52-week-multicenter-open-label-study
#2
Joseph R Calabrese, Na Jin, Brian Johnson, Pedro Such, Ross A Baker, Jessica Madera, Peter Hertel, Jocelyn Ottinger, Joan Amatniek, Hiroaki Kawasaki
BACKGROUND: The long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) was recently approved for maintenance treatment of bipolar I disorder (BP-I). The purpose of this study was to evaluate the safety, tolerability, and efficacy of AOM 400 as long-term maintenance treatment for BP-I. METHODS: This open-label multicenter study evaluated the effectiveness of AOM 400 as maintenance treatment for BP-I by assessing safety and tolerability (primary objective) and efficacy (secondary objective)...
June 10, 2018: International Journal of Bipolar Disorders
https://www.readbyqxmd.com/read/29868849/effectiveness-of-long-acting-injectable-vs-oral-antipsychotics-in-patients-with-schizophrenia-a-meta-analysis-of-prospective-and-retrospective-cohort-studies
#3
Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, Stefan Leucht, Mark Olfson, John M Kane, Christoph U Correll
Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs) should improve medication adherence and reduce relapses in schizophrenia. However, meta-analyses of randomized trials and mirror-image studies yielded inconsistent results. Nonrandomized cohort studies with parallel comparisons of LAIs and OAPs offer a third design to examine this issue. We meta-analyzed cohort studies with ≥24 weeks duration and hospitalization data. Primary outcome was hospitalization rate, ie, number of hospitalizations per person-year...
April 6, 2018: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/29860947/letter-to-the-editor-is-paliperidone-palmitate-more-effective-than-other-long-acting-injectable-antipsychotics
#4
Mitesh Desai, Annette Wooller, Arunas Lignugaris, Srihari Gopal
No abstract text is available yet for this article.
June 4, 2018: Psychological Medicine
https://www.readbyqxmd.com/read/29858836/correction-to-long-acting-injectable-second-generation-antipsychotics-an-update-and-comparison-between-agents
#5
Michael W Jann, Scott R Penzak
1. In Page 244, under General Pharmacokinetic Principles, Column 1-the following sentence should come after reference 21.
June 2, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29851063/the-risk-of-alzheimer-s-disease-associated-with-benzodiazepines-and-related-drugs-a-nested-case-control-study
#6
V Tapiainen, H Taipale, A Tanskanen, J Tiihonen, S Hartikainen, A-M Tolppanen
OBJECTIVE: To assess the association between benzodiazepine and related drug (BZDR) use and risk of Alzheimer's disease (AD) with cumulative consumption and duration of use based models. METHOD: A nationwide nested case-control study of all Finnish community-dwelling persons who received clinically verified AD diagnosis in 2005-2011 (N = 70 719) and their matched controls (N = 282 862). AD diagnosis was based on DSM-IV and NINCDS-ADRDA criteria. BZDR purchases were extracted from the Prescription Register since 1995...
May 31, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29790360/-current-and-future-pharmacotherapy-of-severe-psychiatric-disorders
#7
Eva Češková
Despite of tremendous development in CNS research, current treatment is suboptimal especially in severe mental disorders. In medicine, there are two main methods of improving the healthcare provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring, but also implementation of general trends into the clinical practice. New pharmacological options include drugs aimed at other than monoaminergic systems and old drugs used before the psychopharmacological era...
2018: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/29777648/reasons-for-discontinuation-of-implanon-among-users-in-buffalo-city-metropolitan-municipality-south-africa-a-cross-sectional-study
#8
Khungelwa Patricia Mrwebi, Daniel Ter Goon, Eyitayo Omolara Owolabi, Oladele Vincent Adeniyi, Eunice Seekoe, Anthony Idowu Ajayi
Early discontinuation of implanon, a long-acting, reversible contraceptive among reproductive age women in South Africa is a serious public health concern. The aim of this study was to examine the reasons for discontinuation of implanon among its previous users. This descriptive cross-sectional study involved 188 consecutively selected participants in two large family planning clinics in Buffalo Metropolitan Municipality, East London, South Africa. Descriptive statistics was conducted using SPSS version 22...
March 2018: African Journal of Reproductive Health
https://www.readbyqxmd.com/read/29776316/a-systematic-review-and-combined-analysis-of-therapeutic-drug-monitoring-studies-for-oral-paliperidone
#9
Georgios Schoretsanitis, Edoardo Spina, Christoph Hiemke, Jose de Leon
This article includes a combined analysis of therapeutic drug monitoring (TDM) studies and a review of the marketer's data on pharmacological mechanisms. Areas covered: An article search led to the inclusion of 21 paliperidone studies in the systematic review plus 2 case reports. Paliperidone clearance was calculated from: 1) steady-state studies using concentration/dose (C/D) ratios, and 2) single-dose studies describing 24-hour area under the curve calculations. The marketed extended-release formulation has 28% bioavailability...
May 18, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29766576/predictive-factors-of-overall-functioning-improvement-in-patients-with-chronic-schizophrenia-and-schizoaffective-disorder-treated-with-paliperidone-palmitate-and-aripiprazole-monohydrate
#10
Paolo Girardi, Antonio Del Casale, Chiara Rapinesi, Georgios D Kotzalidis, Francesca Splendori, Claudio Verzura, Giada Trovini, Serena Sorice, Dario Carrus, Iginia Mancinelli, Anna Comparelli, Sergio De Filippis, Antonio Francomano, Andrea Ballerini, Andrea Marcellusi, Francesco S Mennini, Giuseppe Ducci, Gabriele Sani, Maurizio Pompili, Roberto Brugnoli
BACKGROUND: Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE: The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI...
May 15, 2018: Human Psychopharmacology
https://www.readbyqxmd.com/read/29765242/claims-based-proxies-of-patient-instability-among-commercially-insured-adults-with-schizophrenia
#11
Charles Ruetsch, Hyong Un, Heidi C Waters
Objective: Schizophrenia (Sz) patients are among the highest utilizers of hospital-based services. Prevention of relapse is in part a treatment goal in order to reduce hospital admissions. However, predicting relapse is a challenge, particularly for payers and disease management firms with only access to claims data. Understandably, such organizations have had little success predicting relapse. A tool that allows payers to identify patients at elevated risk of relapse could facilitate targeted interventions prior to relapse and avoid rehospitalization...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29764266/impact-of-paliperidone-palmitate-one-month-formulation-on-relapse-prevention-in-patients-with-schizophrenia-a-post-hoc-analysis-of-a-one-year-open-label-study-stratified-by-medication-adherence
#12
Tianmei Si, Nan Li, Huafei Lu, Shangli Cai, Jianmin Zhuo, Christoph U Correll, Lili Zhang, Yu Feng
BACKGROUND: Limited data are available to help identify patients with schizophrenia who are most likely to benefit from long-acting injectable antipsychotics. AIM: The purpose of this study was to investigate the efficacy of long-acting injectable antipsychotic paliperidone palmitate one-month formulation for preventing relapses, factors influencing time to first relapse, and the effect of different antipsychotic adherence levels on time to first relapse in Chinese patients with schizophrenia...
May 1, 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29734130/baseline-results-from-the-european-non-interventional-antipsychotic-long-acting-injection-in-schizophrenia-alto-study
#13
Pierre-Michel Llorca, Julio Bobes, W Wolfgang Fleischhacker, Stephan Heres, Nicholas Moore, Nawal Bent-Ennakhil, Christophe Sapin, Jean-Yves Loze, Anna-Greta Nylander, Maxine X Patel
BACKGROUND: The Antipsychotic Long-acTing injection in schizOphrenia (ALTO) study was a non-interventional study across several European countries examining prescription of long-acting injectable (LAI) antipsychotics to identify sociodemographic and clinical characteristics of patients receiving and physicians prescribing LAIs. ALTO was also the first large-scale study in Europe to report on the use of both first- or second-generation antipsychotic (FGA- or SGA-) LAIs. METHODS: Patients with schizophrenia receiving a FGA- or SGA-LAI were enrolled between June 2013 and July 2014 and categorized as incident or prevalent users...
May 4, 2018: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/29722547/adherence-and-economic-impact-of-paliperidone-palmitate-versus-oral-atypical-antipsychotics-in-a-medicare-population
#14
Kruti Joshi, Erik Muser, Yihua Xu, Phil Schwab, Manasi Datar, Brandon Suehs
AIM: To compare adherence, healthcare utilization and costs among real world, Medicare-eligible patients with schizophrenia using long-acting injectable paliperidone palmitate (PP) versus oral atypical antipsychotics. Patients & methods: Historical cohort study used Medicare Advantage claims data. Inverse probability of treatment weighting was applied to adjust for baseline differences. 12-month adherence, healthcare utilization and costs were compared. RESULTS: Patients using PP were more adherent (proportion of days covered ≥0...
May 3, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29713451/effectiveness-of-paliperidone-long-acting-injection-in-clinical-practice
#15
Paul Nicholas Deslandes, Elan Haf Ward, Kathryn Norris, Robert David Sewell
Background: The efficacy of the long-acting injectable formulation of the antipsychotic paliperidone (paliperidone palmitate) has been investigated in randomized controlled trials. Due to the nature of study designs, these may not be representative of usual clinical practice. The aim of this study was to assess the clinical effectiveness of the long-acting injectable antipsychotic paliperidone palmitate using treatment continuation at 1 year as an outcome. Methods: Patients were initiated on paliperidone palmitate prior to December 2014 in a single health board in Wales (UK)...
May 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29713100/do-long-acting-injectable-antipsychotics-prevent-or-delay-hospital-readmission
#16
Thomas J Maestri, Lisa M Mican, Heather Rozea, Jamie C Barner
Introduction: Long-acting injectable (LAI) antipsychotics were developed as a way to decrease pill burden and simplify medication regimens by allowing less frequent administration to assist with medication adherence. Methods: The purpose of this study was to determine whether LAI antipsychotics prevent or delay hospital readmission in patients with a known history of medication non-adherence. The study is a retrospective evaluation of 240 men and women 18-65 years of age diagnosed with bipolar disorder, schizophrenia, or schizoaffective disorder discharged from an inpatient state hospital over a 2 year period of time on a LAI antipsychotic (fluphenazine LAI, haloperidol LAI, risperidone LAI or paliperidone LAI) or oral antipsychotic...
March 13, 2018: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/29694243/budget-impact-analysis-of-long-acting-injectable-aripiprazole-once-monthly-400-mg-in-bipolar-i-disorder-in-the-usa
#17
Margarida Augusto, Mallik Greene, Maëlys Touya, Samantha Min Sweeney, Heidi Waters
AIM: To estimate the budget impact (BI) of introducing aripiprazole once-monthly 400 mg/300 mg (AOM 400) in the maintenance monotherapy treatment of bipolar I disorder versus long-acting injectables, oral antipsychotics and best supportive care. METHODS: A BI model was developed from a US-payer perspective using treatment-related, hospitalization and adverse event management cost estimates for a hypothetical 1,000,000-member health plan over a 5-year period. RESULTS: Market share of AOM 400 was predicted to increase from 0...
April 25, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29676242/converting-oral-to-long-acting-injectable-antipsychotics-a-guide-for-the-perplexed-corrigendum
#18
Jonathan M Meyer
No abstract text is available yet for this article.
April 2018: CNS Spectrums
https://www.readbyqxmd.com/read/29623634/a-review-of-clinical-and-economic-evaluations-applied-to-psychotropic-therapies-used-in-the-treatment-of-schizophrenia-in-argentina
#19
REVIEW
Gisela Paula González, Nebel Silvana Moscoso, Fernando Pablo Lago
Schizophrenia is considered a serious mental disorder that affects over 21 million people worldwide, and is associated with disability that frequently affects the patient's educational and working performance. In Argentina, two of the most widely used antipsychotics in the treatment of this disorder are haloperidol and risperidone. Both are provided free to patients without health coverage in public healthcare facilities. In this paper we seek to review the clinical and economic benefits of prescribing psychotropic therapies based on haloperidol (a first-generation antipsychotic that is part of the butyrophenone group of drugs) versus risperidone [an atypical or second-generation antipsychotic (neuroleptic) drug] in adult patients who have been diagnosed with schizophrenia...
October 23, 2017: PharmacoEconomics Open
https://www.readbyqxmd.com/read/29579528/decision-making-capacity-for-treatment-of-psychotic-patients-on-long-acting-injectable-antipsychotic-treatment
#20
Maria Nystazaki, Katerina Pikouli, Eva-Maria Tsapakis, Maria Karanikola, Dimitrios Ploumpidis, Giorgos Alevizopoulos
OBJECTIVE: Providing informed, consent requires patients' Decision-Making Capacity for treatment. We evaluated the Decision Making Capacity of outpatients diagnosed with schizophrenia and schizoaffective disorder on treatment with Long Acting Injectable Antipsychotic medication. METHOD: This is a retrospective, cross-sectional, correlational study conducted at two Depot Clinics in Athens, Greece. Participants included 65 outpatients diagnosed with schizophrenia and schizoaffective disorder on treatment with Long Acting Injectable Antipsychotics...
April 2018: Archives of Psychiatric Nursing
keyword
keyword
81198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"